Hangzhou Zhongmei Huadong Pharmaceutical is an API manufacturer based in China. It holds 12 active US drug master files across a filed portfolio of 10 molecules. Its filings concentrate with US FDA and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 18 August 2023 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3003995556 |
| Molecule | Regulators | Docs |
|---|---|---|
| Mupirocin | SFDA (Saudi Arabia), US FDA | 3 |
| Fondaparinux | US FDA | 2 |
| Daptomycin | US FDA | 1 |
| Insulin Aspart | US FDA | 1 |
| Insulin Degludec | US FDA | 1 |
| Pantoprazole | US FDA | 1 |
| Polymyxin B | US FDA | 1 |
| Semaglutide | US FDA | 1 |
| Tacrolimus | US FDA | 1 |
| Voclosporin | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 5 | 1 |
| MINSA (CR) | 1 | None |
Choose your molecules and target markets. Hangzhou Zhongmei Huadong Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free